$2
Qui Tam / Federal Fraud / Off-Label Marketing
Case results reflect publicly available information reported by the listed law firms. They are not results obtained by ThatCarHitMe.com. Every case is unique and must be evaluated on its own facts. Prior results do not guarantee a similar outcome. The results shown are not necessarily representative of all results obtained by these firms. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers.
Case Details
Johnson & Johnson has agreed for its subsidiary Janssen Pharmaceuticals to plead guilty to criminal charges and Johnson & Johnson will pay $2.2 Billion to resolve criminal and civil liability arising from their unlawful promotion of certain prescription drugs. The global resolution is one of the largest health care fraud settlements in U.S. history, including criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 Billion. The government’s case against Johnson & Johnson and Janssen was based partly on a qui tam lawsuit filed by attorney Thomas W. Sheridan of the law firm of Sheridan and Murray, LLC on behalf of a former marketing manager at Janssen. The lawsuit filed by Sheridan provided the government with information relating to a range of improper marketing practices on the part of Johnson & Johnson/Janssen relating to the drug Risperdal from 1999 through 2005 and the drug Invega from 2007 through 2009. Johnson & Johnson/Janssen promoted the sale and use of its drug Risperdal for individuals and specific conditions for which it was not approved as safe and effective by the FDA. Johnson & Johnson/Janssen improperly promoted the sale and use of Risperdal for behavioral disturbances in elderly dementia patients, children and adolescents, and individuals with mental retardation and developmental disabilities. The lawsuit also provided information regarding Johnson & Johnson/Janssen’s illegal payments to health care professionals and long-term pharmacy care providers to improperly promote and prescribe Risperdal in violation of the Federal Anti-Kickback Statute.
Additional Notes
Johnson & Johnson subsidiary, Janssen Pharmaceuticals, Inc., has agreed to plead guilty to two counts of introducing a misbranded drug, Risperdal, into interstate commerce. The civil settlement resolves claims relating to the Johnson & Johnson/Janssen drugs Risperdal, Invega, and Natrecor. The government’s case was based partly on a qui tam lawsuit filed by attorney Thomas W. Sheridan on behalf of a former marketing manager at Janssen. The settlement includes criminal fines and forfeiture totaling $485 million and civil settlements with the federal government and states totaling $1.72 Billion.